{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:41:10Z","timestamp":1792806070221,"version":"4.5.0"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T00:00:00Z","timestamp":1696809600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Bayer and Orion Pharma"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>In the ARASENS trial (NCT02799602), darolutamide in combination with androgen-deprivation therapy (ADT) and docetaxel significantly reduced the risk of death by 32.5% (HR, 0.68; 95% CI, 0.57-0.80; P\u2005&amp;lt;\u2005.0001) compared with placebo plus ADT with docetaxel in patients with metastatic hormone-sensitive prostate cancer (mHSPC). We present efficacy and safety of darolutamide versus placebo in Black patients from ARASENS.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients and Methods<\/jats:title>\n                  <jats:p>Patients with mHSPC were randomized 1:1 to darolutamide 600 mg or placebo twice daily in combination with ADT and docetaxel. The primary endpoint was overall survival. Key secondary endpoints included time to castration-resistant prostate cancer (CRPC) and safety.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In ARASENS, 54 Black patients received darolutamide (n\u2005=\u200526) or placebo (n\u2005=\u200528) plus ADT and docetaxel. In Black patients, overall survival favored darolutamide versus placebo (median, not reached vs. 38.7 months; stratified HR, 0.41; 95% CI, 0.17-1.02), with 4-year survival rates of 62% versus 41%. The darolutamide group also had longer time to CRPC compared with the placebo group (median, not reached vs .12.6 months; HR, 0.09; 95% CI, 0.02-0.30). The safety profile of darolutamide in Black patients was consistent with that observed for the overall ARASENS population (grade 3\/4 treatment-emergent adverse events, TEAEs: 61.5% vs. 66.1%; serious TEAEs: 42.3% vs. 44.8%).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In this small population of Black patients with mHSPC from the ARASENS trial, darolutamide was associated with an improvement in survival and time to CRPC and was well tolerated. Efficacy and safety findings in Black patients were consistent with the overall ARASENS population.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyad254","type":"journal-article","created":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T18:23:06Z","timestamp":1696875786000},"page":"235-243","source":"Crossref","is-referenced-by-count":7,"title":["Efficacy and Safety of Darolutamide in Combination With Androgen-Deprivation Therapy and Docetaxel in Black Patients From the Randomized ARASENS Trial"],"prefix":"10.1093","volume":"29","author":[{"given":"Neal D","family":"Shore","sequence":"first","affiliation":[{"name":"Carolina Urologic Research Center\/Genesis Care , Myrtle Beach, SC , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maha","family":"Hussain","sequence":"additional","affiliation":[{"name":"Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Feinberg School of Medicine , Chicago, IL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Saad","sequence":"additional","affiliation":[{"name":"Centre Hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al, University of Montreal , Montreal, Quebec , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Fizazi","sequence":"additional","affiliation":[{"name":"Institut Gustave Roussy, University of Paris-Saclay , Villejuif , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cora N","family":"Sternberg","sequence":"additional","affiliation":[{"name":"Englander Institute for Precision Medicine, Weill Cornell Department of Medicine, Meyer Cancer Center, New York-Presbyterian Hospital , New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Crawford","sequence":"additional","affiliation":[{"name":"University of California San Diego School of Medicine , San Diego, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Tombal","sequence":"additional","affiliation":[{"name":"Division of Urology, IREC, Cliniques Universitaires Saint Luc , UCLouvain , Brussels , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Nordquist","sequence":"additional","affiliation":[{"name":"XCancer\/GU Research Network , Omaha, NE , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Cookson","sequence":"additional","affiliation":[{"name":"University of Oklahoma Stephenson Cancer Center , Oklahoma City, OK , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Verholen","sequence":"additional","affiliation":[{"name":"Bayer Consumer Care , Basel , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Jhaveri","sequence":"additional","affiliation":[{"name":"Bayer Healthcare Pharmaceuticals , Inc., Whippany, NJ , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shankar","family":"Srinivasan","sequence":"additional","affiliation":[{"name":"Bayer Healthcare Pharmaceuticals , Inc., Whippany, NJ , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R","family":"Smith","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Cancer Center , Boston, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,10,9]]},"reference":[{"key":"2024030500074915400_CIT0001","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume-title":"CA Cancer J Clin","author":"Sung","year":"2021"},{"key":"2024030500074915400_CIT0002","first-page":"17","article-title":"Cancer statistics, 2023","volume-title":"CA Cancer J Clin","author":"Siegel","year":"2023"},{"key":"2024030500074915400_CIT0003","first-page":"1656","article-title":"Genomic testing in localized prostate cancer can identify subsets of African Americans with aggressive disease","volume-title":"J Natl Cancer Inst","author":"Awasthi","year":"2022"},{"key":"2024030500074915400_CIT0004","first-page":"975","article-title":"Association of black race with prostate cancer-specific and other-cause mortality","volume-title":"JAMA Oncol","author":"Dess","year":"2019"},{"key":"2024030500074915400_CIT0005","first-page":"1683","article-title":"Survival of African American and non-Hispanic white men with prostate cancer in an equal-access health care system","volume-title":"Cancer","author":"Riviere","year":"2020"},{"key":"2024030500074915400_CIT0006","article-title":"Care in an equal access system delays prostate cancer progression in minorities [poster]","author":"Rasmussen","year":"2023"},{"key":"2024030500074915400_CIT0007","first-page":"403","article-title":"Overall survival of black and white men with metastatic castration-resistant prostate cancer treated with docetaxel","volume-title":"J Clin Oncol","author":"Halabi","year":"2019"},{"key":"2024030500074915400_CIT0008","first-page":"737","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume-title":"N Engl J Med","author":"Sweeney","year":"2015"},{"key":"2024030500074915400_CIT0009","first-page":"686","article-title":"Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial","volume-title":"Lancet Oncol","author":"Fizazi","year":"2019"},{"key":"2024030500074915400_CIT0010","first-page":"2294","article-title":"Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study","volume-title":"J Clin Oncol","author":"Chi","year":"2021"},{"key":"2024030500074915400_CIT0011","first-page":"1616","article-title":"Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer","volume-title":"J Clin Oncol","author":"Armstrong","year":"2022"},{"key":"2024030500074915400_CIT0012","first-page":"1695","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2x2 factorial design","volume-title":"Lancet","author":"Fizazi","year":"2022"},{"key":"2024030500074915400_CIT0013","first-page":"1132","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume-title":"N Engl J Med","author":"Smith","year":"2022"},{"key":"2024030500074915400_CIT0014","first-page":"1536","article-title":"Impact of ethnicity on the outcome of men with metastatic, hormone-sensitive prostate cancer","volume-title":"Cancer","author":"Bernard","year":"2017"},{"key":"2024030500074915400_CIT0015","first-page":"930","article-title":"Clinical outcomes in men of diverse ethnic backgrounds with metastatic castration-resistant prostate cancer","volume-title":"Ann Oncol","author":"Halabi","year":"2020"},{"key":"2024030500074915400_CIT0016","first-page":"12007","article-title":"Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies","volume-title":"Sci Rep","author":"Moilanen","year":"2015"},{"key":"2024030500074915400_CIT0017","first-page":"527","article-title":"Evaluation of clinically relevant drug-drug interactions and population pharmacokinetics of darolutamide in patients with nonmetastatic castration-resistant prostate cancer: results of pre-specified and post hoc analyses of the phase III ARAMIS trial","volume-title":"Target Oncol","author":"Shore","year":"2019"},{"key":"2024030500074915400_CIT0018","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.23.00041","article-title":"Darolutamide plus androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer by disease volume and risk subgroups in the phase III ARASENS trial","volume-title":"J Clin Oncol","author":"Hussain","year":"2023"},{"key":"2024030500074915400_CIT0019","first-page":"13","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume-title":"N Engl J Med","author":"Chi","year":"2019"},{"key":"2024030500074915400_CIT0020","first-page":"2974","article-title":"ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer","volume-title":"J Clin Oncol","author":"Armstrong","year":"2019"},{"key":"2024030500074915400_CIT0021","first-page":"956","article-title":"Clinical outcomes and racial disparities in metastatic hormone-sensitive prostate cancer in the era of novel treatment options","volume-title":"Oncologist","author":"Smith","year":"2021"},{"key":"2024030500074915400_CIT0022","first-page":"220","article-title":"Multi-institutional analysis of the clinical and genomic characteristics of black patients with metastatic hormone-sensitive prostate cancer","volume-title":"Oncologist","author":"Freeman","year":"2022"},{"key":"2024030500074915400_CIT0023","first-page":"533070","article-title":"Lack of racial survival differences in metastatic prostate cancer in national cancer data base (NCDB): a different finding compared to non-metastatic disease","volume-title":"Front Oncol","author":"Vengaloor Thomas","year":"2020"},{"key":"2024030500074915400_CIT0024","first-page":"397","article-title":"Racial disparities in prostate cancer among black men: epidemiology and outcomes","volume-title":"Prostate Cancer Prostatic Dis","author":"Chowdhury-Paulino","year":"2022"},{"key":"2024030500074915400_CIT0025","first-page":"1101","article-title":"Disparities in castration-resistant prostate cancer trials","volume-title":"J Clin Oncol","author":"Spratt","year":"2015"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/29\/3\/235\/56831417\/oyad254.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/29\/3\/235\/56831417\/oyad254.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T00:08:12Z","timestamp":1709597292000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/29\/3\/235\/7302202"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,9]]},"references-count":25,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,10,9]]},"published-print":{"date-parts":[[2024,3,4]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyad254","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,3,1]]},"published":{"date-parts":[[2023,10,9]]}}}